Clinical trials of NaV1.7 inhibitors.
| Compound [sponsor] | Condition/indication | Study phase | Study status | Identifiera | Ref. |
|---|---|---|---|---|---|
| Vixotrigine/raxatrigine/BIIB074/CNV1014802/GSK1014802 [Biogen/Convergence/GlaxoSmithKline] | HV (SD, resting motor threshold) | 1 | Completed 2008 | NCT00488566 | 113, 114 |
| HV (MD) | 1 | Completed 2008 | NCT00908154 | ||
| HV (SD, electrical stimulation) | 1 | Terminated 2009 | NCT00964288 | ||
| HV (MD, ambulatory blood pressure) | 1 | Completed 2009 | NCT00955396 | ||
| Lumbosacral radiculopathy (MD) | 2 | Completed 2012 | NCT01561027 | ||
| Trigeminal neuralgia (MD) | 2a | Completed 2014 | NCT01540630 | ||
| HV (MD, age, gender) | 1 | Completed 2015 | NCT02359344 | ||
| HV (MD, DDI) | 1 | Completed 2016 | NCT02551497 | ||
| HV (MD, DDI) | 1 | Completed 2016 | NCT02698267 | ||
| HV (SD, hot ADME) | 1 | Completed 2016 | NCT02751905 | ||
| IEM (MD) | 2a | Completed 2017 | NCT02917187 | ||
| HV (SD, MD, race) | 1 | Completed 2017 | NCT02831517 | ||
| HV (SD, RBA) | 1 | Completed 2017 | NCT02951221 | ||
| HV (MD, DDI) | 1 | Completed 2017 | NCT03385525 | ||
| HV (MD, DDI) | 1 | Completed 2018 | NCT03324685 | ||
| Lumbosacral radiculopathy (MD) | 2 | Completed 2018 | NCT02935608 | ||
| Lumbosacral radiculopathy (MD) | 2 | Terminated 2019 | NCT02957617 | ||
| Small fibre neuropathy (MD) | 2 | Terminated 2021 | NCT03339336 | ||
| Trigeminal neuralgia (MD) | 3 | Not yet recruiting 2021 | NCT03070132 | 59 | |
| Trigeminal neuralgia (MD) | 3 | Not yet recruiting 2021 | NCT03637387 | 59 | |
| Funapide/XEN402/XPF-002/TV-45070/FX301 [Xenon/Teva/Flexion] | IEM (MD, oral) | 2a | Completed 2010 | NCT01090622 | 115 |
| PHN (MD, ointment) | 2a | Completed 2011 | NCT01195636 | 116 | |
| IEM (MD, ointment) | 2a | Completed 2012 | NCT01486446 | ||
| HV (MD, ointment) | 1 | Completed 2015 | NCT02215941 | ||
| Knee osteoarthritis (MD, ointment) | 2 | Completed 2015 | NCT02068599 | ||
| PHN (MD, ointment) | 2 | Completed 2017 | NCT02365636 | ||
| Postoperative pain (SD, local injection) | 1 | Recruiting 2021 | NCT04826328 | ||
| PF-05089771 [Pfizer/Icagen] | HV (SD, micro-dosing, oral and intravenous) | 1 | Completed 2010 | NCT01165736 | 117 |
| HV (SD, exploratory pharmacodynamics) | 1 | Completed 2011 | NCT01259882 | ||
| HV (MD) | 1 | Completed 2011 | NCT01365637 | ||
| HV (SD, RBA) | 1 | Completed 2012 | NCT01563497 | ||
| Postoperative dental pain (SD) | 2 | Completed 2012 | NCT01529346 | ||
| HV (SD, RBA) | 1 | Completed 2012 | NCT01690351 | ||
| HV and knee OA (MD) | 1 | Completed 2012 | NCT01529671 | ||
| HV (MD, titration) | 1 | Completed 2013 | NCT01772264 | ||
| IEM (SD) | 2 | Completed 2013 | NCT01769274 | ||
| HV (SD, RBA) | 1 | Completed 2013 | NCT01854996 | ||
| HV (SD, MD, DDI) | 1 | Completed 2013 | NCT01934569 | ||
| HV (SD, pain model) | 1 | Completed 2015 | NCT02349607 | 118 | |
| Diabetic peripheral neuropathy (MD) | 2 | Completed 2015 | NCT02215252 | 119 | |
| AZD3161 [AstraZeneca] | HV (SD, UVC, intradermal injection) | 1 | Completed 2011 | NCT01240148 | |
| DSP-2230 [Sumitomo Dainippon/Sunovion] | HV (SD, MD, RBA) | 1 | Completed 2013 | ISRCTN07951717 | |
| HV (SD, capsaicin and UVB) | 1 | Completed 2013 | ISRCTN80154838 | ||
| HV (MD, renal function) | 1 | Completed 2013 | ISRCTN02543559 | ||
| DS-1971a [Daiichi Sankyo] | HV (SD) | 1 | Completed 2014 | NCT02107885 | |
| HV (MD) | 1 | Completed 2014 | NCT02190058 | ||
| HV (SD, age, gender, race) | 1 | Completed 2014 | NCT02261376 | ||
| HV (SD, RBA) | 1 | Completed 2015 | NCT02266940 | ||
| HV (MD, DDI) | 1 | Completed 2015 | NCT02473627 | ||
| HV (MD, gender) | 1 | Completed 2015 | NCT02564861 | ||
| Diabetic PNMD) | 2 | Withdrawn 2016 | NCT02673866 | ||
| Radiculopathy attributable to LSS (MD) | 2 | Withdrawn 2016 | JapicCTI-163 193 | ||
| GDC-0276/RG7893 [Xenon/Genentech/Roche] | HV (SD, RBA) | 1 | Withdrawn 2016 | NCT02856152 | 98 |
| GDC-0310/RG6029 [Xenon/Genentech/Roche] | HV (SD, MD, RBA) | 1 | Completed 2017 | NCT02742779 | |
| BIIB095 [Biogen/Convergence] | HV (SD, MD) | 1 | Completed 2019 | NCT03454126 | |
| HV and diabetic peripheral neuropathy | 1b | Withdrawn 2021 | NCT04106050 | ||
| CC8464/APS1807 [Chromocell/Astellas] | HV (SD, MD, RBA, DDI) | 1 | Completed | Not registered | |
| DSP-3905 [Sumitomo Dainippon/Sunovion] | HV | 1 | Not disclosed | Not registered |
a
From ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home), ISRCTN registry (https://www.isrctn.com/) and Japic Clinical Trials Information (https://www.clinicaltrials.jp/cti-user/common/Top.jsp).